58. Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2mutations.Rebbeck TR(1), Friebel TM(1), Friedman E(2), Hamann U(3), Huo D(4), Kwong A(5),Olah E(6), Olopade OI(4), Solano AR(7), Teo SH(8), Thomassen M(9), WeitzelJN(10), Chan TL(11), Couch FJ(12), Goldgar DE(13), Kruse TA(9), Palmero EI(14),Park SK(15)(16)(17), Torres D(3)(18), van Rensburg EJ(19), McGuffog L(20),Parsons MT(21), Leslie G(20), Aalfs CM(22), Abugattas J(23), Adlard J(24), Agata S(25), Aittomäki K(26), Andrews L(27), Andrulis IL(28)(29), Arason A(30), Arnold N(31), Arun BK(32), Asseryanis E(33), Auerbach L(33), Azzollini J(34), BalmañaJ(35), Barile M(36), Barkardottir RB(30), Barrowdale D(20), Benitez J(37)(38),Berger A(39), Berger R(40), Blanco AM(41), Blazer KR(10), Blok MJ(42), BonadonaV(43), Bonanni B(36), Bradbury AR(44), Brewer C(45), Buecher B(46), Buys SS(47), Caldes T(48), Caliebe A(49), Caligo MA(50), Campbell I(51), Caputo SM(46),Chiquette J(52), Chung WK(53), Claes KBM(54), Collée JM(55), Cook J(56), DavidsonR(57), de la Hoya M(48), De Leeneer K(54), de Pauw A(46), Delnatte C(58), DiezO(59), Ding YC(60), Ditsch N(61), Domchek SM(44), Dorfling CM(19), VelazquezC(62), Dworniczak B(63), Eason J(64), Easton DF(20), Eeles R(65), EhrencronaH(66), Ejlertsen B(67); EMBRACE(20), Engel C(68), Engert S(69), Evans DG(70),Faivre L(71), Feliubadaló L(72), Ferrer SF(73), Foretova L(74), Fowler J(75),Frost D(20), Galvão HCR(76), Ganz PA(77), Garber J(78), Gauthier-Villars M(46),Gehrig A(79); GEMO Study Collaborators(80)(81), Gerdes AM(82), Gesta P(83),Giannini G(84), Giraud S(85), Glendon G(86), Godwin AK(87), Greene MH(88),Gronwald J(89), Gutierrez-Barrera A(32), Hahnen E(90), Hauke J(90); HEBON(91),Henderson A(92), Hentschel J(93), Hogervorst FBL(94), Honisch E(95), ImyanitovEN(96), Isaacs C(97), Izatt L(98), Izquierdo A(99), Jakubowska A(89), JamesP(100), Janavicius R(101), Jensen UB(102), John EM(103)(104), Vijai J(105),Kaczmarek K(89), Karlan BY(106), Kast K(107), Investigators K(108), Kim SW(109), Konstantopoulou I(110), Korach J(111), Laitman Y(2), Lasa A(112), Lasset C(43),Lázaro C(72), Lee A(113), Lee MH(114), Lester J(106), Lesueur F(115), LiljegrenA(116), Lindor NM(117), Longy M(118), Loud JT(88), Lu KH(119), Lubinski J(89),Machackova E(74), Manoukian S(34), Mari V(120), Martínez-Bouzas C(121), MatraiZ(122), Mebirouk N(115), Meijers-Heijboer HEJ(123), Meindl A(69), MensenkampAR(124), Mickys U(125), Miller A(126), Montagna M(25), Moysich KB(127), Mulligan AM(128), Musinsky J(105), Neuhausen SL(60), Nevanlinna H(129), Ngeow J(130),Nguyen HP(131), Niederacher D(95), Nielsen HR(9), Nielsen FC(132), NussbaumRL(133), Offit K(134), Öfverholm A(135), Ong KR(136), Osorio A(137), Papi L(138),Papp J(6), Pasini B(139), Pedersen IS(140), Peixoto A(141)(142), Peruga N(89),Peterlongo P(143), Pohl E(90), Pradhan N(105), Prajzendanc K(89), Prieur F(144), Pujol P(145), Radice P(146), Ramus SJ(147)(148), Rantala J(149), RashidMU(3)(150), Rhiem K(90), Robson M(151), Rodriguez GC(152), Rogers MT(153),Rudaitis V(154), Schmidt AY(132), Schmutzler RK(90), Senter L(155), Shah PD(44), Sharma P(156), Side LE(157), Simard J(158), Singer CF(33), Skytte AB(102), SlavinTP(10), Snape K(159), Sobol H(160), Southey M(160)(161), Steele L(60), SteinemannD(162), Sukiennicki G(89), Sutter C(163), Szabo CI(164), Tan YY(39), TeixeiraMR(141)(142), Terry MB(165), Teulé A(166), Thomas A(167), Thull DL(168),Tischkowitz M(169), Tognazzo S(25), Toland AE(170), Topka S(105), TrainerAH(171), Tung N(172), van Asperen CJ(173), van der Hout AH(174), van der KolkLE(94), van der Luijt RB(175), Van Heetvelde M(54), Varesco L(176), Varon-MateevaR(177), Vega A(178), Villarreal-Garza C(179)(180), von Wachenfeldt A(181), WalkerL(182), Wang-Gohrke S(183), Wappenschmidt B(90), Weber BHF(184), YannoukakosD(110), Yoon SY(8), Zanzottera C(34), Zidan J(185), Zorn KK(186), Hutten Selkirk CG(187), Hulick PJ(188), Chenevix-Trench G(21), Spurdle AB(21), Antoniou AC(20), Nathanson KL(44).Author information: (1)Harvard TH Chan School of Public Health and Dana Farber Cancer Institute,Boston, USA.(2)The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, ChaimSheba Medical Center, Ramat Gan 52621, and the Sackler School of Medicine,Tel-Aviv University, Tel-Aviv, Israel.(3)Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),Heidelberg, Germany.(4)Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, USA.(5)The Hong Kong Hereditary Breast Cancer Family Registry, Cancer GeneticsCenter, Hong Kong Sanatorium and Hospital, Hong Kong, China.(6)Department of Molecular Genetics, National Institute of Oncology, Budapest,Hungary.(7)INBIOMED, Faculty of Medicine, University of Buenos Aires/CONICET and CEMIC,Department of Clinical Chemistry, Medical Direction, Buenos Aires, Argentina.(8)Cancer Research Initiatives Foundation, Sime Darby Medical Centre, SubangJaya, Malaysia.(9)Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.(10)Division of Clinical Cancer Genomics, City of Hope Cancer Center, California,USA.(11)Division of Molecular Pathology, Department of Pathology, Hong KongSanatorium & Hospital, Happy Valley, Hong Kong.(12)Department of Laboratory Medicine and Pathology, and Health SciencesResearch, Rochester, USA.(13)Department of Dermatology, University of Utah School of Medicine, Salt LakeCity, USA.(14)Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo,Brazil.(15)Department of Preventive Medicine, Seoul National University College ofMedicine, Seoul, Korea.(16)Department of Biomedical Science, Seoul National University Graduate School, Seoul, Korea.(17)Cancer Research Center, Seoul National University, Seoul, Korea.(18)Institute of Human Genetics, Pontificia Universidad Javeriana, Colombia.(19)Cancer Genetics Laboratory, Department of Genetics, University of Pretoria,South Africa.(20)Centre for Cancer Genetic Epidemiology, Department of Public Health andPrimary Care, University of Cambridge, Cambridge, UK.(21)Genetics and Computational Biology Department, QIMR Berghofer MedicalResearch Institute, Brisbane, Australia.(22)Department of Clinical Genetics, Academic Medical Center, Amsterdam, TheNetherlands.(23)City of Hope Clinical Cancer Genomics Community Research Network, Duarte,USA.(24)Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.(25)Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padua, Italy.(26)Department of Clinical Genetics, Helsinki University Hospital, Helsinki,Finland.(27)Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Australia.(28)Lunenfeld-Tanenbaum Research Institute, Toronto, Canada.(29)Department of Molecular Genetics, University of Toronto, Toronto, Canada.(30)Laboratory of Cell Biology, Department of Pathology, hus 9, Landspitali-LSHv/Hringbraut, 101 Reykjavik, Iceland and BMC (Biomedical Centre), Faculty ofMedicine, University of Iceland, Reykjavik, Iceland.(31)Department of Gynaecology & Oncology, Medical University of Vienna, Austria.(32)Department of Breast Medical Oncology and Clinical Cancer Genetics Program,University Of Texas MD Anderson Cancer Center, Houston, USA.(33)Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna,Vienna, Austria.(34)Unit of Medical Genetics, Department of Medical Oncology and Hematology,Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Instituto Nazionale Tumori (INT), Milan, Italy.(35)Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona,Spain.(36)Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia(IEO), Milan, Italy.(37)Human Genetics Group and Genotyping Unit (CEGEN), Human Cancer GeneticsProgramme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.(38)Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.(39)Dept of OB/GYN, Comprehensive Cancer Center, Medical University of Vienna,Vienna, Austria.(40)The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.(41)UCSF Cancer Genetics and Prevention Program, San Francisco, USA.(42)Department of Clinical Genetics, Maastricht University Medical Center,Maastricht, The Netherlands.(43)Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, 28 rue Laënnec, Lyon, France.(44)Department of Medicine, Abramson Cancer Center, Perelman School of Medicineat the University of Pennsylvania, Philadelphia, USA.(45)Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK.(46)Service de Génétique, Institut Curie, 26 rue d'Ulm, Paris, France.(47)Department of Medicine, Huntsman Cancer Institute, Salt Lake City, USA.(48)Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto deInvestigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica enRed de Cáncer (CIBERONC), Madrid, Spain.(49)Institute of Human Genetics, University Hospital of Schleswig-Holstein, Kiel,Germany.(50)Section of Molecular Genetics, Dept. of Laboratory Medicine, UniversityHospital of Pisa, Pisa, Italy.(51)Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.(52)CRCHU de Quebec-oncologie, Centre des maladies du sein Deschênes-Fabia,Hôpital du Saint-Sacrement, Sainte-Foy, Canada.(53)Departments of Pediatrics and Medicine, Columbia University, New York, USA.(54)Center for Medical Genetics, Ghent University, Gent, Belgium.(55)Department of Clinical Genetics, Family Cancer Clinic, Erasmus UniversityMedical Center, Rotterdam, The Netherlands.(56)Sheffield Clinical Genetics Service, Sheffield Children's Hospital,Sheffield, UK.(57)Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow,UK.(58)Unité d'oncogénétique, ICO-Centre René Gauducheau, Saint Herblain, France.(59)Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Clinical and Molecular Genetics Area, Vall d'Hebron University Hospital, Barcelona, Spain.(60)Department of Population Sciences, Beckman Research Institute of City ofHope, Duarte, USA.(61)Department of Gynaecology and Obstetrics, Ludwig-Maximilian University,Munich, Germany.(62)Cáncer Hereditario, Instituto de Biología y Genética Molecular, IBGM,Universidad de Valladolid, Valladolid, Spain.(63)Institute of Human Genetics, University of Münster, Münster, Germany.(64)Nottingham Clinical Genetics Service, Nottingham University Hospitals NHSTrust, Nottingham, UK.(65)Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHSFoundation Trust, London, UK.(66)Department of Clinical Genetics, Lund University Hospital, Lund, Sweden.(67)Department of Oncology, Rigshospitalet, Copenhagen University Hospital,Copenhagen, Denmark.(68)Institute for Medical Informatics, Statistics and Epidemiology, University ofLeipzig, Leipzig, Germany.(69)Department of Gynaecology and Obstetrics, Division of Tumor Genetics,Klinikum rechts der Isar, Technical University, Munich, Germany.(70)Genomic Medicine, Manchester Academic Health Sciences Centre, Division ofEvolution and Genomic Sciences, University of Manchester, Central ManchesterUniversity Hospitals NHS Foundation Trust, Manchester, UK.(71)Centre de Lutte Contre le Cancer Georges François Leclerc, France and Genomicand Immunotherapy Medical Institute, Dijon University Hospital, Dijon, France.(72)Molecular Diagnostic Unit, Hereditary Cancer Program, ICO-IDIBELL (CatalanInstitute of Oncology-Bellvitge Biomedical Research Institute), Barcelona, Spain.(73)Laboratoire de Génétique Chromosomique, Hôtel Dieu Centre Hospitalier,Chambéry, France.(74)Department of Cancer Epidemiology and Genetics, Masaryk Memorial CancerInstitute, Brno, Czech Republic.(75)Columbus Cancer Council, Ohio State University, Columbus, USA.(76)Oncogenetics Department, Barretos Cancer Hospital, Barretos, Brazil.(77)UCLA Schools of Medicine and Public Health, Division of Cancer Prevention &Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, USA.(78)Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, USA.(79)Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics,Institute of Human Genetics, University of Würzburg, Germany, Würzburg.(80)Department of Tumour Biology, Institut Curie, Paris, France.(81)Institut Curie, Paris, France.(82)Department of Clinical Genetics, Copenhagen, Denmark.(83)Service Régional Oncogénétique Poitou-Charentes, Centre Hospitalier, Niort,France.(84)Department of Molecular Medicine, University La Sapienza, and IstitutoPasteur - Fondazione Cenci-Bolognetti, Rome, Italy.(85)Bâtiment Cheney D, Centre Léon Bérard, Lyon, France.(86)Ontario Cancer Genetics Network: Lunenfeld-Tanenbaum Research Institute,Mount Sinai Hospital, Toronto, Canada.(87)Department of Pathology and Laboratory Medicine, University of Kansas MedicalCenter, Kansas City, USA.(88)Clinical Genetics Branch, DCEG, NCI, NIH, Bethesda, USA.(89)Department of Genetics and Pathology, Pomeranian Medical University,Szczecin, Poland.(90)Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology(CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.(91)The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Netherlands Cancer Institute, Amsterdam, The Netherlands.(92)Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne HospitalsNHS Trust, Newcastle upon Tyne, UK.(93)Institute of Human Genetics, University Leipzig, Leipzig, Germany.(94)Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, TheNetherlands.(95)Department of Gynaecology and Obstetrics, University Hospital Düsseldorf,Heinrich-Heine University, Düsseldorf, Germany.(96)N.N. Petrov Institute of Oncology, St. Petersburg, Russia.(97)Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA.(98)Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK.(99)Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institutd'Investigació Biomèdica de Girona), Catalan Institute of Oncology, Girona,Spain.(100)Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia.(101)Hematology, oncology and transfusion medicine center, Dept. of Molecular andRegenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.(102)Department of Clinical Genetics, Aarhus University Hospital, Aarhus N,Denmark.(103)Department of Epidemiology, Cancer Prevention Institute of California,Fremont, USA.(104)Department of Health Research and Policy (Epidemiology) and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA.(105)Clinical Genetics Research Laboratory, Dept. of Medicine, MemorialSloan-Kettering Cancer Center, New York, USA.(106)Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA.(107)Department of Gynecology and Obstetrics, Medical Faculty and UniversityHospital Carl Gustav Carus, Dresden, Germany.(108)Research Department, Peter MacCallum Cancer Centre, Melbourne, Victoria,Australia and The Sir Peter MacCallum Department of Oncology University ofMelbourne, Parkville, Australia.(109)Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea.(110)Molecular Diagnostics Laboratory, INRASTES (Institute of Nuclear andRadiological Sciences and Technology), National Centre for Scientific Research"Demokritos", Athens, Greece.(111)The Gyneco-Oncology Department, Chaim Sheba Medical Center, Ramat Gan,Israel.(112)Servicio de Genética-CIBERER U705, Hospital de la Santa Creu i Sant Pau,Barcelona, Spain.(113)The Feinstein Institute for Medical Research, Manhasset, USA.(114)Department of Surgery, Soonchunhyang University and Seoul Hospital, Seoul,Korea.(115)Inserm U900, Institut Curie, PSL Research University, Paris, France.(116)Department of Oncology Radiumhemmet and Institution of Oncology andPatology, Karolinska University Hospital and Karolinska Institutet, Solna,Sweden.(117)Department of Health Sciences Research, Mayo Clinic, Scottsdale, USA.(118)Oncogénétique, Institut Bergonié, Bordeaux, France.(119)Department of Gynecological Oncology and Clinical Cancer Genetics Program,University Of Texas MD Anderson Cancer Center, Houston, USA.(120)Centre Antoine Lacassagne, Nice, France.(121)Laboratorio de Genética Molecular, Servicio de Genética, HospitalUniversitario Cruces, BioCruces Health Research Institute, Barakaldo, Spain.(122)Department of Surgery, National Institute of Oncology, Budapest, Hungary.(123)Department of Clinical Genetics, VU University Medical Center, Amsterdam,The Netherlands.(124)Department of Human Genetics, Radboud University Medical Center, Nijmegen,The Netherlands.(125)Vilnius university Santariskiu hospital, National Center of Pathology,Vilnius, Lithuania.(126)NRG Oncology, Statistics and Data Management Center, Roswell Park CancerInstitute, Buffalo, USA.(127)Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, USA.(128)Department of Laboratory Medicine and Pathobiology, University of Toronto,Toronto, Canada.(129)Department of Obstetrics and Gynecology, University of Helsinki and HelsinkiUniversity Hospital, HUS, Finland.(130)Cancer Genetics Service, Division of Medical Oncology, National CancerCentre Singapore, Bukit Merah, Singapore.(131)Institute of Medical Genetics and Applied Genomics, University of Tuebingen,Tuebingen, Germany.(132)Center for Genomic Medicine, Rigshospitalet, University of Copenhagen,Copenhagen, Denmark.(133)Cancer Genetics and Prevention Program, University of California SanFrancisco, San Francisco, USA.(134)Clinical Genetics Research Laboratory, Dept. of Medicine, Cancer Biology andGenetics, Memorial Sloan-Kettering Cancer Center, New York, USA.(135)Department of Clinical Genetics, Sahlgrenska University Hospital,Gothenburg, Sweden.(136)West Midlands Regional Genetics Service, Birmingham Women's HospitalHealthcare NHS Trust, Edgbaston, UK.(137)Human Genetics Group, Human Cancer Genetics Programme, Spanish NationalCancer Research Centre (CNIO), Biomedical Network on Rare Diseases (CIBERER),Madrid, Spain.(138)Unit of Medical Genetics, Department of Biomedical, Experimental andClinical Sciences, University of Florence, Florence, Italy.(139)Department of Medical Sciences, University of Turin, Turin, Italy.(140)Section of Molecular Diagnostics, Department of Biochemistry, AalborgUniversity Hospital, Aalborg, Denmark.(141)Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.(142)Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.(143)IFOM, The FIRC (Italian Foundation for Cancer Research) Institute ofMolecular Oncology, Milan, Italy.(144)Service de Génétique Clinique Chromosomique et Moléculaire, Hôpital Nord, StEtienne, France.(145)Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier, France.(146)Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department ofResearch, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico),Istituto Nazionale Tumori (INT), Milan, Italy.(147)School of Women's and Children's Health, UNSW, Sydney, Australia.(148)The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney,Australia.(149)Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.(150)Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital andResearch Centre, Lahore, Pakistan.(151)Clinical Genetics Services, Dept. of Medicine, Memorial Sloan-KetteringCancer Center, New York, USA.(152)Division of Gynecologic Oncology, North Shore University Health System,University of Chicago, Evanston, USA.(153)All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, UK.(154)Department of Gynecology, Vilnius University Hospital Santariskiu Clinics,Centre of Woman's Health and pathology, Vilnius, Lithuania.(155)Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University,Columbus, USA.(156)Department of Internal Medicine, Division of Oncology, University of Kansas Medical Center, Westwood, USA.(157)North East Thames Regional Genetics Service, Great Ormond Street Hospitalfor Children NHS Trust, London, UK.(158)Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec City, Canada.(159)Medical Genetics Unit, University of London, St George's, UK.(160)Département Oncologie Génétique, Prévention et Dépistage, InstitutPaoli-Calmettes, Marseille Medical School-AM University, Marseille, France.(161)Genetic Epidemiology Laboratory, Department of Pathology, University ofMelbourne, Parkville, Australia.(162)Institute of Cell and Molecular Pathology, Hannover Medical School,Hannover, Germany.(163)Institute of Human Genetics, University Hospital Heidelberg, Heidelberg,Germany.(164)National Human Genome Research Institute, National Institutes of Health,Bethesda, USA.(165)Department of Epidemiology, Columbia University, New York, USA.(166)Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (BellvitgeBiomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Gran Viade l'Hospitalet, Barcelona, Spain.(167)Department of Health Sciences Research, Mayo Clinic, Rochester, USA.(168)Department of Medicine, Magee-Womens Hospital, University of PittsburghSchool of Medicine, Pittsburgh, USA.(169)Program in Cancer Genetics, Departments of Human Genetics and Oncology,McGill University, Montreal, Canada.(170)Division of Human Genetics, Departments of Internal Medicine and CancerBiology and Genetics, Comprehensive Cancer Center, The Ohio State University,Columbus, USA.(171)Parkville Familial Cancer Centre, Royal Melbourne Hospital, Melbourne,Australia.(172)Department of Medical Oncology, Beth Israel Deaconess Medical Center,Massachusetts, USA.(173)Department of Clinical Genetics, Leiden University Medical Center, Leiden,The Netherlands.(174)Department of Genetics, University Medical Center, Groningen University,Groningen, The Netherlands.(175)Department of Medical Genetics, University Medical Center, Utrecht, TheNetherlands.(176)Unit of Hereditary Cancer, Department of Epidemiology, Prevention andSpecial Functions, IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico)AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.(177)Institute of Human Genetics, Campus Virchov Klinikum, Berlin, Germany.(178)Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de MedicinaXenómica-USC, CIBERER, IDIS, Santiago de Compostela, Spain.(179)Departamento de Investigacion y de Tumores Mamarios del, Instituto Nacional de Cancerologia, Mexico City, Mexico.(180)Centro de Cancer de Mama del Hospital Zambrano Hellion, Tecnologico deMonterrey, San Pedro Garza Garcia, Mexico.(181)Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.(182)Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK.(183)Department of Gynaecology and Obstetrics, University Hospital, Ulm, Germany.(184)Institute of Human Genetics, Regensburg University, Regensburg, Germany.(185)Institute of Oncology, Rivka Ziv Medical Center, Zefat, Israel.(186)Magee-Womens Hospital, University of Pittsburgh School of Medicine,Pittsburgh, USA.(187)Center for Medical Genetics, North Shore University Health System, Evanston,USA.(188)Medical Director, Center for Medical Genetics, NorthShore UniversityHealthSystem, Clinical Assistant Professor of Medicine, University of ChicagoPritzker School of Medicine, Evanston, USA.The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have beenreported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2(CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutationsidentified in the CIMBA database. We observed substantial variation in mutationtype and frequency by geographical region and race/ethnicity. In addition toknown founder mutations, mutations of relatively high frequency were identifiedin specific racial/ethnic or geographic groups that may reflect founder mutationsand which could be used in targeted (panel) first pass genotyping for specificpopulations. Knowledge of the population-specific mutational spectrum in BRCA1and BRCA2 could inform efficient strategies for genetic testing and may justify amore broad-based oncogenetic testing in some populations.© 2018 Wiley Periodicals, Inc.DOI: 10.1002/humu.23406 PMCID: PMC5903938 [Available on 2019-05-01]PMID: 29446198 